Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kintara Therapeutics Inc (NQ: KTRA ) 0.2096 +0.0207 (+10.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Kintara Therapeutics Inc TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor July 08, 2024 Via ACCESSWIRE Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones July 01, 2024 Via ACCESSWIRE TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) June 03, 2024 Via ACCESSWIRE KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA April 05, 2024 From Kahn Swick & Foti, LLC Via Business Wire KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders April 03, 2024 From Halper Sadeh LLC Via Business Wire Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement April 03, 2024 Via ACCESSWIRE Is Kintara Therapeutics A Hidden Gem? December 30, 2022 Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year. Via MarketBeat Exposures Product Safety Kintara Therapeutics (NASDAQ: KTRA) Granted Orphan Drug Status for VAL-083 and the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) December 15, 2022 Kintara Therapeutics, Inc. (NASDAQ: KTRA) is engaged as a biopharmaceutical company, which is focused on the research and development of Via Spotlight Growth Exposures Product Safety Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up December 01, 2022 FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... Via FinancialNewsMedia Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.